Study of QL2109 vs. Darzalex Faspro for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new medicine, QL2109, against an approved drug, Darzalex Faspro, for people with multiple myeloma that has worsened after prior treatments. It aims to see if QL2109 works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to have measurable signs of multiple myeloma, such as certain proteins in your blood or urine.
- You must have had at least one prior treatment that included a PI drug (like bortezomib) and lenalidomide, and if you only had one line of treatment, your disease got worse on lenalidomide.
- Your cancer must show clear signs of worsening based on your doctor's assessment.
- You need to be in fairly good health (able to take care of yourself and out of bed more than half the day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new biosimilar drug called QL2109, which is similar to daratumumab (a treatment for multiple myeloma). Healthy men aged 18-50 will receive one dose to see how the body processes it and if it causes any side effects.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
This trial tests a new drug, BCD-264, compared to Darzalex (daratumumab) alone for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if BCD-264 works better than Darzalex in controlling the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.